Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Creative Biolabs is one of the world’s leading contract organizations (CRO) that has extensive experience in preclinical drug discovery. Our employees are at the core of our success, with the ambition to improving health and increasing access to quality health solutions worldwide. We believe when curious, courageous and collaborative people like you are brought together, a big difference will be made for the development of innovate medicines.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant monoclonal antibody to TGF-beta. Fresolimumab (GC1008) is a human monoclonal antibody and an immunomodulator. It is intended for the treatment of idiopathic pulmonary fibrosis (IPF), focal segmental glomerulosclerosis, and cancer (kidney cancer and melanoma).
IgG4 - kappa
A synthetic peptide (17 aa) derived from C terminal human TGF beta 3 protein.
Suitable for use in FC, IP, ELISA, Neut, FuncS, IF, ICC and most other immunological methods.
Tested positive against native human antigen.
Immunoglobulin G4-kappa, anti-[Homo sapiens transforming growth factor beta (TGFB or TGFbeta or TGF-beta,including TGF-beta-1 or TGFB1, TGF-beta-2 or TGFB2 or G-TsF and TGF-beta-3 or TGFB3)], Homo sapiens monoclonal antibody
Predicted N terminal
H chain: QVQLVQS ; L chain: ETVLTQS
>95.0% as determined by analysis by SDS-PAGE.
Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.
On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for TGF-beta.
enzyme binding; eukaryotic cell surface binding; growth factor activity; protein N-terminus binding; protein binding; protein heterodimerization activity; protein homodimerization activity; type II transforming growth factor beta receptor binding; type II